Clinical Trial

Stretta Versus Conservative Treatment

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Gastroesophageal reflux disease (GERD) is one of the most common diseases of the gastrointestinal tract. Obesity is a significant risk factor for GERD; however, treatment outcomes in obese patients remain challenging. In the Czech Republic, therapeutic options are currently limited to conservative treatment, including pharmacotherapy and lifestyle modifications, or surgical interventions, both of which have known limitations. Stretta is a minimally invasive endoscopic therapy using radiofrequency energy delivered to the esophagogastric junction (EGJ) and cardia, aimed at enhancing the antireflux barrier. This study evaluates the effectiveness and safety of the Stretta procedure compared to conservative treatment in managing GERD. Initially designed to compare outcomes between obese and non-obese populations, the study was expanded to include all GERD patients due to recruitment challenges and the need to meet strict eligibility criteria. These criteria ensure reliable results by focusing on patients with confirmed pathological GERD while excluding those with hiatal hernias ≥ 2 cm, severe esophagitis, or functional esophageal disorders such as hypersensitivity. The study aims to provide comprehensive data on the use of Stretta in the Czech Republic and its role in GERD management.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-03-11; most recent amendment 2025-01-05.
Trial Details
NCT Number NCT05781347
Lead Sponsor Military University Hospital, Prague
Conditions GERD
Enrollment 50 participants
Start Date 2022-09-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-07